Novartis has bought biotech AveXis for $8.7 billion, adding a potential gene therapy for the rare disease spinal muscular atrophy (SMA) to its pipeline.
Eli Lilly and Sigilon Therapeutics have announced a collaboration to develop therapies based around capsules of genetically-engineered stem cells to treat type 1 diabetes.
Celgene’s chief operating officer and inflammatory diseases guru Scott Smith has quit the company, in the aftermath of the FDA’s rejection of a key multiple sclerosis pill, and a late-stage
